Minerva Neurosciences | NERV - Market Capitalization


Minerva Neurosciences reported $32.8M in Market Capitalization this September of 2026, considering the latest stock price and the number of outstanding shares.





Market Capitalization Change Date
Acadia Pharmaceuticals USD 4.33B 537M Jun/2026
Adma Biologics USD 2.15B 2.19B Mar/2026
ALKERMES USD 8.73B 2.85B Jun/2026
Alterity Therapeutics Limited AUD 39M 17M Sep/2026
AstraZeneca USD 289.99B 11.26B Jun/2026
BioCryst Pharmaceuticals USD 2.54B 880M Jun/2026
Bristol-Myers Squibb USD 117.66B 6.17B Jun/2026
Cipla INR 1.18T 194.93B Jun/2026
Clal Biotechnology ILS 43.45M 8.92M Mar/2026
Compugen USD 620.29M 475.62M Mar/2026
CSL USD 55.89B 20.42B Dec/2025
Eli Lilly USD 1.13T 260.54B Jun/2026
GlaxoSmithKline GBP 80.14B 3.66B Jun/2026
Halozyme Therapeutics USD 9.28B 1.63B Jun/2026
Ionis Pharmaceuticals USD 13.1B 642M Jun/2026
J&J USD 611.36B 32.21B Jun/2026
Merck USD 317.37B 20.27B Jun/2026
Neurocrine Biosciences USD 16.95B 3.7B Jun/2026
Novartis USD 240.59B 67.17B Jun/2026
Novavax USD 1.09B 316M Dec/2025
Pfizer USD 138.44B 15.37B Jun/2026
Roche Holding CHF 270B 3.66B Jun/2026
Sanofi EUR 91.15B 9.12B Jun/2026
Takeda JPY 8.2T 809.7B Jun/2026
Vanda Pharmaceuticals USD 279M 6M Dec/2024